

Agreement with Johnson & Johnson
RNS Number : 2349T
Trellus Health PLC
14 January 2025



Trellus Health plc
("Trellus Health", the "Company" or the "Group")

**Trellus Health to Bring Holistic Support to Patients, Working
With a Pharmaceutical Company**

LONDON, U.K. AND NEW YORK, U.S. (14 January 2025). Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate™, a digital platform that integrates data analytics with personalized, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announced it has entered into an agreement with Johnson & Johnson Health Care Systems Inc. to support a pilot in the US to assess the potential for the Trellus Elevate program to support patients with moderately to severely active inflammatory bowel disease (IBD).

As part of the agreement, Trellus Health® will receive an undisclosed upfront licensing fee, along with a fixed monthly management fee. The one-year collaboration will provide eligible patients prescribed a Johnson & Johnson therapy access to Trellus Elevate™.

Patient Support Programs (PSPs), provided by pharmaceutical companies, are designed to help patients manage their medical conditions alongside prescription therapies by offering resources and tailored support. By integrating Trellus Elevate™ into such a program, patients are offered the tools and confidence to navigate the emotional and physical challenges of their condition, stay engaged, adhere to treatment plans, and take control of their health journey.

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:

"We identified the pharmaceutical sector as a key strategic vertical in our September interim results and are excited to announce our first major

collaboration in this vertical. Trellus Elevate™ provides a seamless, end-to-end solution from clinical trials to commercialisation, leveraging our proprietary resilience-based approach to drive trial and patient support success.

"We have reached a therapeutic ceiling with many existing treatments for IBD and it is only by addressing both the mind and body that we can truly break through that barrier. Managing and adhering to treatment regimens for lifelong, incurable immune conditions like IBD can be overwhelming for patients, making comprehensive support essential. By providing holistic wraparound care, we can help patients stay on track with their therapies and empower them to thrive. We look forward to working with Johnson & Johnson and leveraging our Trellus Elevate™ platform and our innovative methodology to help support patients' needs."

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

Trellus Health plc <https://trellushealth.com/>
Dr. Marla Dubinsky, Chief Executive Officer and Co- **Via Walbrook PR**
Founder
Joy Bessenger, Chief Financial Officer

Singer Capital Markets (Nominated Adviser and Tel: +44 (0)20 7496 3000 Broker)
Jen Boorer / James Todd / Jalini Kalaravy

Walbrook PR **Tel: +44 (0)20 7933 8780** or trellus@walbrookpr.com
Paul McManus / Phillip Marriage / **Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082/**
Louis Ashe-Jepson **+44 (0) 7747 515 393**

About Trellus Health plc (www.trellushealth.com)

Trellus Health (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced condition

management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate™ resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

Trellus Health® also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRBIMFTMTIBMBA